Premium
Impact of hormonal therapy prior to radical prostatectomy on the recovery of quality of life
Author(s) -
NAMIKI SHUNICHI,
SAITO SEIICHI,
TOCHIGI TATSUO,
KUWAHARA MASAAKI,
IORITANI NAOMASA,
YOSHIMURA KOJI,
TERAI AKITO,
KOINUMA NOBUO,
ARAI YOICHI
Publication year - 2005
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2005.01014.x
Subject(s) - medicine , prostatectomy , hormonal therapy , urology , quality of life (healthcare) , hormone , prostate cancer , nursing , cancer
Background: We investigated the changes in health‐related quality of life (HRQOL) in patients who underwent prostatectomy (RP) with or without neoadjuvant hormonal therapy (NHT). Methods: A total of 72 patients undergoing direct RP (DRP group) and 26 patients receiving neoadjuvant hormonal therapy (NHT group) were enrolled in the present study. The baseline interview was conducted before RP (not initiation of therapy). Follow‐up interviews were conducted in person at scheduled study visits of 3, 6, and 12 months after surgery. We measured general and disease specific HRQOL with the Medical Outcomes Study 36‐Item Short Form and University of California, Los Angeles Prostate Cancer Index, respectively. Results: At baseline, the NHT group scored statistically lower for not only sexual function ( P < 0.001), but also the general HRQOL, such as role limitations due to physical problems ( P = 0.007), social function ( P = 0.045) and mental health ( P = 0.034), than the DRP group. The NHT group reported lower scores in social function and mental health at 3 months ( P = 0.040 and 0.006, respectively). Patients who received NHT for more than 3 months continued to show significantly lower scores for some HRQOL domains 12 months later. Conclusion: Neoadjuvant hormonal therapy may decrease not only sexual function, but also general HRQOL before surgery. The recovery of HRQOL appeared to be further prolonged in patients who received long‐term NHT.